drugset / Trial / NCT03028870

A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee

NCT03028870

Phase 2 Completed 291 enrolled Purdue Pharma LP Shionogi · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the analgesic efficacy of V120083 twice daily compared to placebo in subjects with moderate to severe chronic pain due to OA of the knee.

Timeline

Start
2017-03-14
Primary completion
2017-11-10
Completion
2017-11-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naproxen Small molecule 500 mg Oral
Subject V120083 Unknown 30 mg Oral
Subject V120083 Unknown 60 mg Oral

Indications